Advertisement

Naloxone Reversal of Opioid-Induced Respiratory Depression with Special Emphasis on the Partial Agonist/Antagonist Buprenorphine

  • Elise Sarton
  • Luc Teppema
  • Albert Dahan
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 605)

Buprenorphine is relatively resistant to reversal by naloxone. We tested the effect of various doses and infusion schemes of naloxone on buprenorphineinduced respiratory depression and compared the data with naloxone-reversal of morphine and alfentanil-induced respiratory depression. Both morphine and alfentanil were easily reversed by low doses of naloxone (0.4 mg). Increasing doses of naloxone caused a bell-shaped reversal curve of buprenorphine with maximal reversal at naloxone doses between 2 and 4 mg. However, reversal was short-lived. The bell-shaped reversal curve may be related to the existence of two μ-opioid receptor subtypes, one mediating the agonist effects of opioids at low dose, the other mediating antagonistic effects at high dose.

Keywords

Respiratory Depression Hypoxic Ventilatory Response OPRM1 Gene Maximal Reversal Baseline Ventilation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dahan, A., DeGoede, J., Berkenbosch, A. and Olievier, I.C.W. (1990) The influence of oxygen on the ventilatory response to carbon dioxide in man. J. Physiol. (Lond.) 428, 485–499.Google Scholar
  2. Dahan, A., Sarton, E., Teppema, L. and Olievier, C. (1998) Sex-related differences in the influence of morphine on ventilatory control in humans. Anesthesiology 88, 903–913.CrossRefPubMedGoogle Scholar
  3. Dahan, A., Yassen, A., Bijl, H., Romberg, R., Sarton, E., Teppema, L., Olofsen, E. and Danhof, M. (2005) Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesth. 94, 825–834.CrossRefPubMedGoogle Scholar
  4. Dahan, A., Yassen, A., Romberg, R., Sarton, E., Teppema, L., Olofsen, E. and Danhof, M. (2006) Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br. J. Anaesth. 96, 627–632.CrossRefPubMedGoogle Scholar
  5. van Dorp, E., Yassen, A., Sarton, E., Romberg, R., Olofsen, E., Teppema, L., Danhof, M. and Dahan, A. (2006) Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 105, 51–57.CrossRefPubMedGoogle Scholar
  6. Romberg, R.R., Olofsen, E., Bijl, H., Taschner, P.E.M., Teppema, L.J., Sarton, E.Y., van Kleef, J.W. and Dahan, A. (2005) Polymorphism of the -opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102, 522–530.CrossRefPubMedGoogle Scholar
  7. Sarton, E., Olofsen, E., Romberg, R., den Hartigh, J., Kest, B., Nieuwenhuijs, D., Burm, A., Teppema, L. and Dahan, A. (2000) Sex differences in morphine analgesia. Anesthesiology 93, 1245–254.CrossRefPubMedGoogle Scholar
  8. Yassen, A., Olofsen, E., Dahan, A. and Danhof, M. (2005) Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J. Pharmacol. Exp. Ther. 313, 1136–1149.CrossRefPubMedGoogle Scholar
  9. Yassen A., Olofsen, E., Romberg, R., Sarton, E., Danhof, M. and Dahan, A. (2006) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 104, 1232–1242.CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Elise Sarton
    • 1
  • Luc Teppema
    • 1
  • Albert Dahan
    • 1
  1. 1.Department of AnesthesiologyLeiden University Medical CenterThe Netherlands

Personalised recommendations